Literature DB >> 6186370

Subcellular distribution of androgen receptors in human normal, benign hyperplastic, and malignant prostatic tissues: characterization of nuclear salt-resistant receptors.

E R Barrack, P Bujnovszky, P C Walsh.   

Abstract

Two populations of nuclear androgen receptors have been characterized in human prostatic tissue, and the levels and proportions of each were found to differ in normal prostates, benign hyperplastic prostates (BPH), and malignant prostates. A significant percentage (35 to 50%) of total nuclear androgen receptors was associated with the salt-resistant nuclear matrix fraction. The remainder were easily extracted from nuclei by 0.6 M KCl. Optimal conditions for measuring receptors in both compartments involved the use of an inhibitor of proteolysis (phenylmethylsulfonyl fluoride) and the omission of dithiothreitol from buffers. In the presence of dithiothreitol, most of the nuclear salt-resistant receptors were rendered salt extractable. Cytosol androgen receptor levels were not significantly different in normal, BPH, or malignant prostatic tissues. In contrast, the levels and distribution of nuclear salt-extractable and salt-resistant androgen receptors exhibited characteristic patterns. Compared to normal prostatic tissue, nuclear salt-extractable receptors were significantly elevated in both BPH and cancer, whereas nuclear salt-resistant receptors were elevated in BPH but not in cancer. The ratio of salt-extractable to salt-resistant receptors was approximately 1:1 in both normal and BPH tissues and 2:1 in cancer. In addition, a microassay has been developed for the measurement of androgen receptors in the three subcellular compartments of needle biopsy specimens of prostatic cancer. Studies are in progress to determine whether the measurement of both nuclear salt-extractable and salt-resistant receptors may improve the usefulness of receptor levels to predict the hormonal responsiveness of prostatic cancer.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6186370

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

1.  Cytosolic and nuclear androgen receptor activity in the cancer of the larynx.

Authors:  M Marugo; G Cordone; L Fazzuoli; O Rocchetti; D Bernasconi; C Laviosa; D Bessarione; G Giordano
Journal:  J Endocrinol Invest       Date:  1987-10       Impact factor: 4.256

2.  Human hepatocellular carcinoma tumor xenografts. Their androgen-receptor status and growth responses to castration.

Authors:  A A Dunk; N Kyprianou; P Davies; H C Thomas
Journal:  Dig Dis Sci       Date:  1988-04       Impact factor: 3.199

3.  5-alpha-Reductase Inhibitors Prevent the Progression of Benign Prostatic Hyperplasia.

Authors:  Claus G Roehrborn
Journal:  Rev Urol       Date:  2003

4.  5-alpha-Reductase Inhibitors Prevent the Progression of Benign Prostatic Hyperplasia.

Authors:  Claus G Roehrborn
Journal:  Rev Urol       Date:  2003

Review 5.  The Role of Heat Shock Protein 70 Subfamily in the Hyperplastic Prostate: From Molecular Mechanisms to Therapeutic Opportunities.

Authors:  Xun Fu; Huan Liu; Jiang Liu; Michael E DiSanto; Xinhua Zhang
Journal:  Cells       Date:  2022-06-28       Impact factor: 7.666

6.  The effect of molybdate on the intracellular distribution of estrogen receptor in mammary tumors.

Authors:  C B Lazier; J Richman; K Lonergan
Journal:  Breast Cancer Res Treat       Date:  1984       Impact factor: 4.872

7.  Serum dioxin, testosterone, and subsequent risk of benign prostatic hyperplasia: a prospective cohort study of Air Force veterans.

Authors:  Amit Gupta; Norma Ketchum; Claus G Roehrborn; Arnold Schecter; Corinne C Aragaki; Joel E Michalek
Journal:  Environ Health Perspect       Date:  2006-11       Impact factor: 9.031

8.  Serum pituitary and sex steroid hormone levels in the etiology of prostatic cancer--a population-based case-control study.

Authors:  S O Andersson; H O Adami; R Bergström; L Wide
Journal:  Br J Cancer       Date:  1993-07       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.